Evidence map›Paper›PMID 38978645›Full record

ArticlemedRxiv : the preprint server for health sciences2025

A proteomic signature of healthspan.

Chia-Ling Kuo, Peiran Liu, Gabin Drouard, Eero Vuoksimaa, Jaakko Kaprio, Miina Ollikainen, Zhiduo Chen, Luke C Pilling, Janice L Atkins, Richard H Fortinsky and 2 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Chia-Ling KuoDepartment of Public Health Sciences, University of Connecticut Health Center, Farmington Connecticut, USA.
Peiran LiuThe Cato T. Laurencin Institute for Regenerative Engineering, University of Connecticut Health Center, Farmington, Connecticut, USA.
Gabin DrouardMinerva Foundation Institute for Medical Research, Helsinki, Finland.
Eero VuoksimaaMinerva Foundation Institute for Medical Research, Helsinki, Finland.ORCID 0000-0002-6534-3667
Jaakko KaprioMinerva Foundation Institute for Medical Research, Helsinki, Finland.ORCID 0000-0002-3716-2455
Miina OllikainenMinerva Foundation Institute for Medical Research, Helsinki, Finland.
Zhiduo ChenUConn Center on Aging, University of Connecticut Health Center, Farmington, CT, USA.
Luke C PillingDepartment of Clinical and Biomedical Sciences, University of Exeter, Exeter, UK.ORCID 0000-0002-3332-8454
Janice L AtkinsDepartment of Clinical and Biomedical Sciences, University of Exeter, Exeter, UK.ORCID 0000-0003-4919-9068
Richard H FortinskyUConn Center on Aging, University of Connecticut Health Center, Farmington, CT, USA.
George A KuchelUConn Center on Aging, University of Connecticut Health Center, Farmington, CT, USA.
Breno S DinizDepartment of Public Health Sciences, University of Connecticut Health Center, Farmington Connecticut, USA.

Funding

Research Education ComponentP30AG067988 · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · 2025 to 2025
$1.3M
NIA NIH HHS P30 AG067988
6 · The paper itself

Abstract

The focus of aging research has shifted from increasing lifespan to enhancing healthspan to reduce the time spent living with disability. Despite significant efforts to develop biomarkers of aging, few studies have focused on biomarkers of healthspan. We developed a proteomics-based signature of healthspan (healthspan proteomic score (HPS)) using proteomic data from the Olink Explore 3072 assay in the UK Biobank Pharma Proteomics Project (53,018 individuals and 2920 proteins). A lower HPS was associated with higher mortality risk and several age-related conditions, such as COPD, diabetes, heart failure, cancer, myocardial infarction, dementia, and stroke. HPS showed superior predictive accuracy for these outcomes compared to other biological age measures. Proteins associated with HPS were enriched in hallmark pathways such as immune response, inflammation, cellular signaling, and metabolic regulation. The external validity was evaluated using the Essential Hypertension Epigenetics study with proteomic data also from the Olink Explore 3072 and complementary epigenetic data, making it a valuable tool for assessing healthspan and as a potential surrogate marker to complement existing proteomic and epigenetic biological age measures in geroscience-guided studies.

Identifiers

PMID38978645
PMCPMC11230312

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.